Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
67 results about "Psychosis drug" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A psychotic state induced by excessive dosage of certain therapeutic drugs as well as drugs of abuse. Therapeutic drugs often associated with drug-induced psychosis include atropine-like drugs, chloral hydrate, steroids, and isoniazid.
Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
InactiveUS7973043B2Preventing disease progression/modifyingDelaying/preventing relapseBiocideNervous disorderInitial treatmentTherapy resistant
The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.
Owner:MIGALY PETER
Use of cannabinoids in combination with an Anti-psychotic medicament
ActiveUS20110038958A1High activityLess degree of activityBiocideSenses disorderPsychosis drugTypical antipsychotic
The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
Owner:GW PHARMA LTD
Acute treatment of headache with phenothiazine antipsychotics
Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.
Owner:ALEXZA PHARMA INC
Use of cannabinoids in combination with an anti-psychotic medicament
ActiveUS9017737B2High activityLess degree of activityBiocideSenses disorderTypical antipsychoticPsychosis drug
The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
Owner:GW PHARMA LTD
Acute Treatment of Headache with Phenothiazine Antipsychotics
Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.
Owner:ALEXZA PHARMA INC
Pharmaceutical compositions comprising fatty glycerol esters
ActiveUS20130267504A1Patient compliance is goodOptimizing pharmacological profileBiocideNervous disorderPsychosis drugGlycerol
The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.
Owner:ALKERMES PHARMA IRELAND LTD
Pharmaceutical compositions comprising fatty acid esters
ActiveUS20130267503A1Patient compliance is goodOptimizing pharmacological profileBiocideNervous disorderPsychosis drugEthyl ester
The present invention relates to an injectable, pharmaceutical composition comprising a C1-6 alkyl ester of a C10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.
Owner:ALKERMES PHARMA IRELAND LTD
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
ActiveUS20160339011A1Improve therapeutic indexUseful in treatmentOrganic active ingredientsNervous disorderPsychosis drugSchizo-affective type
New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.
Owner:NEUROCRINE BIOSCI INC
Kit for detecting anti-psychosis drugs in serum and plasma by liquid chromatography tandem mass spectrometry method and application thereof
InactiveCN109085263AReduce matrix effectThe test result is accurateComponent separationPsychosis drug9-Hydroxyrisperidone
The invention provides a kit for detecting anti-psychosis drugs in a serum and plasma by a liquid chromatography tandem mass spectrometry method. The kit comprises drug standards: amsulpiride, aripiprazole, dehydroaripiprazole, chlorpromazine, clozapine, n-desmethylclozapine, risperidone, 9-hydroxyrisperidone, quetiapine, olanzapine, ziprasidone; drug internal standard compounds: amplepiride-d5, aripiprazole-d8, chlorpromazine-d3, clozapine-d8, risperidone-d4, 9-hydroxyrisperidone-d4, quetiapine-d8, olanzapine-d8, ziprasidone-d8; drug extraction compounds: methanol solution 60% (volume ratio),acetonitrile solution 20%, isopropanol solution 10%, purified water 10%; negative plasma; and a diluent: 50% aqueous methanol solution. The kit can be used to simultaneously detect anti-psychosis drugs and active metabolites thereof, the detection time is short and the flux is large.
Owner:HANGZHOU BAICHEN MEDICAL INSTR CO LTD +1
Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
InactiveUS20060252744A1Reduce exposureMany symptomBiocideNervous disorderPsychosis drugNeuropsychiatric disease
Disclosed herein is the use of N-desmethylclozapine (NDMC) and related compounds to treat a variety of neuropsychiatric diseases including psychosis. It is shown that NDMC and related compounds are agonists or partial agonists at D2 and D3 dopamine receptors and thus may be effective as a dopamine stabilizing agent, allowing it to be used to treat or provide reduced incidence of Extrapyramidal symptoms (EPS) and / or tardive dyskinesias (TD). Also disclosed is administering NDMC and related compounds in combination with other anti-psychotic agents.
Owner:ACADIA PHARMA INC
Thienoisoxazolyl-and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists
The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
Owner:AVENTISUB II INC
Method for identifying antipsychotic drug candidates
The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.
Owner:TECHNION RES & DEV FOUND LTD
Method for classification of anti-psychotic drugs
The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.
Owner:THE ROCKEFELLER UNIV
In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
ActiveUS20090176800A1High activityImprove cognitive impairmentCompounds screening/testingNervous disorderPsychosis drugScreening method
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Acute treatment of headache with phenothiazine antipsychotics
Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.
Owner:ALEXZA PHARMA INC
Aripiprazole formulations having increased injection speeds
Owner:ALKERMES PHARMA IRELAND LTD
Medicine for treating schizophrenia
ActiveCN102078566ALittle side effectsLow recurrence rateHeavy metal active ingredientsNervous disorderPsychosis drugDisease
The invention relates to a medicine for treating schizophrenia, relating to a medicine composition for treating schizophrenia, in particular to a medicine for treating schizophrenia by using fossil, ore, Chinese animal medicine and Chinese herbal medicines as raw materials. The formula comprises the following components: raw keel, ochre, rhubarb, wrinkled gianthyssop, tabasheer, lapis chloriti, arisaema with bile, albizia bark, datura flower, japanese sweetflag, radix curcumae, radix bupleuri, eupatorium, burreed tuber, curcuma zedoary, poria with hostwood and magnet. The medicine has therapeutic effects on schizophrenia, is safe and effective, has quick effect-taking, high total effective rate, few side effects and low recurernce rate when matched with a low dose of antipsychotic for treating schizophrenia, and is low in price, convenient to carry and take, and especially suitable for long-term maintenance treatment in a recovery phase and a stable phase.
Owner:苏建峰
Intranasal delivery of antipsychotic drugs
InactiveUS20060039869A1Rapid systemic availabilityAvoidance of hepatic first metabolismBiocidePowder deliveryPsychosis drugNebulizer
An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose sprayer. A method of treating a psychotic episode also is provided, the method including the step of delivering an antipsychotic drug, such as haloperidol, intranasally in an amount effective to control the psychotic episode.
Owner:UNIV OF KENTUCKY RES FOUND
7-keto DHEA for psychiatric use
InactiveUS20080070879A1Improve depressive symptomsFunction increaseBiocideOrganic active ingredientsAnti-Anxiety AgentsDisease
The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.
Owner:SAGEMAN SHARON +1
Benzoisothiazole compounds and use in preparation of antipsychotic drugs
ActiveUS20160096811A1Poor efficacyMeet demandOrganic active ingredientsNervous disorderDiseaseGeometric isomer
Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D3 receptor, 5-HT1A receptor and 5-HT2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.
Owner:SHANGHAI INST OF PHARMA IND
Kit for simultaneously detecting multiple antipsychotic drugs in serum
The invention discloses a kit for simultaneously detecting multiple antipsychotic drugs in serum. An LC-MS / MS method is adopted; 16 common antipsychotic drugs can be detected at one time; the kit is simple in pretreatment process, low in cost, high in sensitivity and high in specificity; separation and detection of the antipsychotic drug are completed within 5 min, accuracy and precision basicallymeet the requirements, the kit can be used for quantitative analysis of the clinical antipsychotic drug, and a reliable detection method is provided for monitoring the treatment concentration of theclinical antipsychotic drug.
Owner:NANJING PINSHENG MEDICAL TECH CO LTD
7-keto DHEA for psychiatric use
InactiveUS8124598B2Improve depressive symptomsFunction increaseOrganic active ingredientsNervous disorderAnti-Anxiety AgentsPsychosis drug
The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.
Owner:SAGEMAN SHARON +1
Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone
ActiveUS8835438B2High activityImprove cognitive impairmentCompounds screening/testingNervous disorderPsychosis drugTypical antipsychotic
A method of evaluating memory / learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found.An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.
Owner:SUMITOMO PHARMA CO LTD
High-dispersity composition of low-dose drugs and preparation method of high-dispersity composition
ActiveCN108524454ANo residueHigh dissolution rateOrganic active ingredientsPharmaceutical product form changeAnalgesics drugsPsychosis drug
The invention discloses a high-dispersity composition of low-dose drugs and a preparation method of the high-dispersity composition, aiming to solve the problem that existing preparation methods for the low-dose drugs cannot meet requirements on content uniformity and influences of parameter change amplification in the production process on physicochemical properties of the low-dose drugs are remarkable. The high-dispersity composition and the preparation method thereof have the advantages that the low-dose drugs are prepared by the twin-screw extrusion technology for the first time; Vitamin Danalogue drugs, glucocorticoid drugs, antipsychotics, antipyretic and analgesic drugs and other low-dose drugs are screened as research objects; preparation of solid preparations through a twin-screwextruder is studied deeply; the content uniformity meets requirements of the pharmacopeia.
Owner:NANJING HERON PHARM CO LTD
Application of Chinese medicinal composition in preparing medicament for treating affective disorder
The invention discloses application of a Chinese medicinal composition in preparing a medicament for treating affective disorder. The medicament is mainly prepared from ginseng, leech, scorpion, ground beeltle, cicada slough, red peony root, sandalwood, rosewood heart wood, frankincense, spine date seed and borneol, and is refined by modern pharmaceutical technology. Clinical experiments prove that the medicament has the dual-directional regulation effect of Chinese medicaments, can treat the affective disorder effectively, and has safety and reliability, remarkable curative effect and small side effect.
Owner:HEBEI YILING MEDICINE INST
Antipsychotic drug related metabolism syndrome susceptible gene and application thereof
The invention provides an antipsychotic drug related metabolism syndrome susceptible gene and an application thereof, and concretely relates to a use of a separate single-nucleotide polymorphism (SNP) site-containing polynucleotide or a detection reagent thereof in the preparation of kits for detecting antipsychotic drug related metabolism syndrome susceptibility. The SNP site in the polynucleotide corresponds to human chromosome 17p11.2 region (chr17:17708129(GRCh37 / hg19)), rs11654081, C to T. The susceptibility of individuals to antipsychotic drug related metabolism syndrome can be judged in an adjuvant manner through detecting the gene and SNP, and a new approach is provided for diagnosis and corresponding treatment of the syndrome; and additionally, the discovery of the gene and the SNP also provides a new drug target for developing drugs for treating the related metabolism syndrome, and the gene and the SNP can be used as syndrome patient regression and prognosis molecule markers.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
InactiveUS20070160537A1High activityImprove cognitive impairmentCompounds screening/testingNervous disorderPsychosis drugTypical antipsychotic
A method of evaluating memory / learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Method for classification of anti-psychotic drugs
The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.
Owner:THE ROCKEFELLER UNIV
Novel assay for screening antipsychotic drugs
InactiveUS20060252103A1Easy to observeQuick and easy determinationCompound screeningApoptosis detectionPsychosis drugSerotonin 2A Receptors
A novel assay method suitable for screening of novel antipsychotics wherein the drugs may be selected based on the differential internalization of the 5-HT2A receptor in neuronal and non-neuronal cell lines effect for it to predict the extrapyramidal symptoms that may be induced by an antipsychotic without having to carry out in vivo experiments.
Owner:TATA INSTITUTE OF FUNDAMENTAL RESEARCH
7-KETO DHEA for Psychiatric Use
InactiveUS20100160274A1Treatment and amelioration of psychiatric disordersIncrease libidoOrganic active ingredientsNervous disorderPsychosis drugClinical psychology
The present invention relates to the use of 3-acetyl-7-oxo-dehydroepiandrosterone (7-keto DHEA) in the preparation of a medicament to treat or ameliorate psychiatric conditions. The present invention relates to methods of using compositions comprising 7-keto DHEA to treat or ameliorate psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions.
Owner:SAGEMAN SHARON +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com